Access the full text.
Sign up today, get DeepDyve free for 14 days.
(1995)
Flowcyto-metric analysis of apoptosis and Bcl-2 in human solid neoplasm
N. Gursan, M. Karakök, I. Sari, Gursan (2001)
THE RELATIONSHIP BETWEEN EXPRESSION OF P53/BCL‐2 AND HISTOPATHOLOGICAL CRITERIA IN BREAST INVASIVE DUCTAL CARCINOMASInternational Journal of Clinical Practice, 55
B. Hsu, M. Marin, S. Brisbay, K. McConnell, T. McDonnell (1994)
Expression of bcl-2 gene confers multidrug resistance to chemotherapy- induced cell deathCancer Bulletin, 46
M. Greaves (1996)
Is telomerase activity in cancer due to selection of stem cells and differentiation arrest?Trends in genetics : TIG, 12 4
K. Porter‐Jordan, M. Lippman (1994)
Overview of the biologic markers of breast cancer.Hematology/oncology clinics of North America, 8 1
J. Lotem, L. Sachs (1993)
Regulation by bcl-2, c-myc, and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation-competent and -defective myeloid leukemic cells.Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research, 4 1
G. Arpino, S. Green, D. Allred, D. Lew, S. Martino, C. Osborne, R. Elledge (2004)
HER-2 Amplification, HER-1 Expression, and Tamoxifen Response in Estrogen Receptor-Positive Metastatic Breast CancerClinical Cancer Research, 10
C. Greider (1994)
Mammalian telomere dynamics: healing, fragmentation shortening and stabilization.Current opinion in genetics & development, 4 2
P. Scott, Kenneth Smith, Richard Poulsom, A. Benedetti, R. Bicknell, A. Harris (1998)
Differential expression of vascular endothelial growth factor mRNA vs protein isoform expression in human breast cancer and relationship to eIF-4E.British Journal of Cancer, 77
D. Page (1991)
Prognosis and Breast Cancer: Recognition of Lethal and Favorable Prognostic TypesThe American Journal of Surgical Pathology, 15
G. Núñez, L. London, D. Hockenbery, Martha Alexander, J. Mckearn, S. Korsmeyer (1990)
Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines.Journal of immunology, 144 9
O. Beahrs, M. Myers (1992)
Manual for Staging of Cancer
M. Baba, T. Hideshima, T. Shinohara, J. Yamashita, T. Shirakusa (1996)
Immunohistochemical analysis of bcl-2 and p53 protein in breast carcinoma.International journal of oncology, 8 2
L. Owen-Schaub, Wei Zhang, J. Cusack, L. Angelo, M. Sybil, Santee, T. Fujiwara, J. Roth, A. Deisseroth, Wei-wei Zhang, E. Kruzel, R. Radinsky (1995)
Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expressionMolecular and Cellular Biology, 15
(1993)
Bcl-2 modulation of apoptosis produced by anti-cancer drugs: resistance pathways
(1984)
Abbott ER-EIA Monoclonal package insert
N. Kim, Mieczyslaw Piatyszek, K. Prowse, C. Harley, M. West, P. Ho, G. Coviello, W. Wright, S. Weinrich, J. Shay (1994)
Specific association of human telomerase activity with immortal cells and cancer.Science, 266 5193
P. Hellemans, P. Dam, J. Weyler, A. Oosterom, P. Buytaert, E. Marck (1995)
Prognostic value of bcl-2 expression in invasive breast cancer.British Journal of Cancer, 72
(2000)
Bcl-2 over-expression and hypoxia synergistically act to modulate VEGF expression and in vivo angiogenesis in a breast cancer cell line
R. Walker, S. Dearing, D. Lane, J. Varley (1991)
Expression of p53 protein in infiltrating and in‐situ breast carcinomasThe Journal of Pathology, 165
D. Wynford‐Thomas (1997)
Proliferative lifespan checkpoints: cell-type specificity and influence on tumour biology.European journal of cancer, 33 5
C. Harley (1995)
9 Telomeres and AgingCold Spring Harbor Monograph Archive, 29
E. Yonish-Rouach, Dalia Resnftzky, J. Lotem, L. Sachs, A. Kimchi, M. Oren (1991)
Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6Nature, 352
D. McGee (1986)
A program for logistic regression on the IBM PC.American journal of epidemiology, 124 4
S. Montero, C. Guzman, Carmela Vargas, C. Ballestín, H. Cortés-Funes, R. Colomer (2001)
Prognostic Value of Cytosolic p53 Protein in Breast CancerTumor Biology, 22
E. Hiyama, T. Saeki, K. Hiyama, S. Takashima, J. Shay, Y. Matsuura, T. Yokoyama (2000)
Telomerase activity as a marker of breast carcinoma in fine‐needle aspirated samplesCancer Cytopathology, 90
M. Younes, R. Lebovitz, K. Bommer, P. Cagle, D. Morton, S. Khan, R. Laucirica (1995)
p53 accumulation in benign breast biopsy specimens.Human pathology, 26 2
S. Eissa, L. Seada (1998)
Quantitation of bcl-2 protein in bladder cancer tissue by enzyme immunoassay: comparison with Western blot and immunohistochemistry.Clinical chemistry, 44 7
Q. Lu, R. Poulsom, Leslie Wong, A. Hanby (1993)
BCL‐2 expression in adult and embryonic non‐haematopoietic tissuesThe Journal of Pathology, 169
G. Morin (1989)
The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeatsCell, 59
(1989)
Molecular cloning (3rd edn.)
R. Elledge, S. Green, L. Howes, G. Clark, M. Berardo, D. Allred, R. Pugh, D. Ciocca, P. Ravdin, J. O'Sullivan, Rivkin Se, S. Martino, C. Osborne (1997)
bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 15 5
489 ROLE OF P53, Bcl-2 AND TELOMERASE ACTIVITY
T. Rohan, W. Hartwick, A. Miller, R. Kandel (1998)
Immunohistochemical detection of c-erbB-2 and p53 in benign breast disease and breast cancer risk.Journal of the National Cancer Institute, 90 17
J. Shay, W. Wright (1996)
The reactivation of telomerase activity in cancer progression.Trends in genetics : TIG, 12 4
SWELLAM
A. Wyllie (1995)
The genetic regulation of apoptosis.Current opinion in genetics & development, 5 1
Kazuo Yashima, S. Milchgrub, Lauren Gollahon, Anirban Maitra, M. Saboorian, Jerry Shay, Adi Gazdar (1998)
Telomerase enzyme activity and RNA expression during the multistage pathogenesis of breast carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research, 4 1
(1994)
Modulation of bcl-2 and ki-67 expression in estrogen-positive human breast cancer by tomoxifen
Miyashita Toshiyuki, John Reed (1995)
Tumor suppressor p53 is a direct transcriptional activator of the human bax geneCell, 80
(1998)
Inhibition of cell growth, and telomerase activity of breast cancer cells in vitro by zidovudine
O. El-ahmady, Eman El-Salahy, Sanaa Eissa, Mohamed Mahmoud, M. Wahab, Ali Khalifa (2000)
Multivariate analysis of bcl-2, apoptosis, P53 and HER-2/neu in breast cancer: a short-term follow-up.Anticancer research, 22 4
C. Holman (1984)
Analysis of interobserver variation on a programmable calculator.American journal of epidemiology, 120 1
M. Bradford (1976)
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.Analytical biochemistry, 72
S. Johnston, J. Salter, K. Maclennan, N. Sacks, J. Mckinna, I. Smith, M. Dowsett (1992)
Short term tamoxifen induces the cytoplasmic expression of c-erbB2 and BCL-2 in er-positive human primary breast cancerThe Breast, 1
W. Domagala, M. Welcker, M. Chosia, M. Karbowniczek, B. Harezga, J. Bártková, J. Bartek, M. Osborn (2001)
p21/WAF1/Cip1 expression in invasive ductal breast carcinoma: relationship to p53, proliferation rate, and survival at 5 yearsVirchows Archiv, 439
A. Henderson (1993)
Assessing Test Accuracy and its Clinical Consequences: A Primer for Receiver Operating Characteristic Curve AnalysisAnnals of Clinical Biochemistry, 30
J. Shay, S. Bacchetti (1997)
A survey of telomerase activity in human cancer.European journal of cancer, 33 5
M. Šimíčková, M. Nekulová, L. Pecen, M. Černoch, M. Vagundová, Z. Pačovský (2001)
Quantitative determination of telomerase activity in breast cancer and benign breast diseases.Neoplasma, 48 4
C. Mueller, U. Riese, H. Kosmehl, R. Dahse, U. Claussen, G. Ernst (2002)
Telomerase activity in microdissected human breast cancer tissues: association with p53, p21 and outcome.International journal of oncology, 20 2
(1992)
Breast cancer update: Prognostic profile markers. Division of specialty lab. INC. How to use prognostic factors in ANN breast cancer patients
Apoptotic cell death represents an important mechanism for the precise regulation of cell numbers, and a defense mechanism against tumor cells. Both bcl‐2 and mutant p53 gene products have been involved in apoptotic pathways. On the other hand, cell proliferation capacity and tumorgenesis have been controlled by telomerase. The purpose of our study is to assess the prognostic significance of additional markers implicated in apoptosis and tumorgenesis. Fifty‐one fresh tissue samples of primary breast carcinoma and 26 tissue samples of benign breast lesions were included in this study. Expression of bcl‐2 in cell lysates and mutant p53 protein in nuclear fraction were measured by Oncogene Science EIA procedures. Telomerase activity was analyzed using the Telomerase‐PCR‐ELISA based on the TRAP (telomerase repeat amplification protocol) method. On the same specimens, steroid hormone receptors (ER and PgR) were measured in cytosol fraction using Abbott EIA assays. In addition, information regarding surgical‐pathological features of the tumor was obtained. Univariate and Multivariate analysis was done to identify variables predictive of poor prognosis. Significant expression of bcl‐2, mutant p53 proteins and relative telomerase activity were observed in malignant cases when compared to benign ones. Univariate analysis revealed significant association in the level of both mutant p53 and relative telomerase activity with tumor size and disease recurrence. Moreover, telomerase activity was significantly expressed in late stages than early ones. Multivariate analysis revealed that bcl‐2, mutant p53, telomerase activity, PgR and age were independent prognostic factors. Among a panel of molecular genetic factors investigated, mutant p53 and relative telomerase activity were strongly associated with disease recurrence; hence they exert a significant prognostic role in breast cancer. IUBMB Life, 56: 483‐490, 2004
IUBMB Life – Wiley
Published: Aug 1, 2004
Keywords: Oncogenes; Apoptosis; Bcl‐2; Mutant P53; Telomerase Activity; Prognostic Factors
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.